No-deal Brexit: MHRA would take on EMA functions for UK

The UK will fall outside of the European Medicines Agency (EMA) in the event of a no-deal Brexit, leaving the Medicines and Healthcare Products Regulatory Agency (MHRA) to take on the functions currently undertaken by the EU for medicines on the UK market.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

EMA settles Brexit dispute; issues drug shortages guidance

8 July 2019 The European Medicines Agency has ended a Brexit legal dispute over its Canary Wharf, London headquarters.

Big Pharma

UK publishes further no-deal Brexit guidance for medicines

8 January 2019 The UK government has published further guidance on the regulation of medicines, medical devices and clinical trials in the event of a no-deal Brexit.

Big Pharma

MHRA seeks public views on no-deal Brexit

4 October 2018 The UK’s Medicines and Healthcare Products Regulatory Agency is seeking industry views on a no-deal Brexit scenario.